Key result
DOAC utilization increases ~190% from 2019 to 2024, surpassing warfarin in the Czech Republic.
Why the study?
DOACs have gradually replaced warfarin globally, but limited data were available regarding the timeline of this transition in the Czech Republic.
Observational
Absolute Event Rate: 22.54% vs 7.78%
p-value: p=<0.01
DOACs have progressively replaced warfarin in the Czech Republic, with total OAC utilization increasing significantly from 2019 to 2024.
Rising DOAC predominance warrants outcome monitoring in Czech cohorts; leaves open drivers and comparative effectiveness.
Background:The patterns of oral anticoagulant (OAC) prescription have significantly changed in recent years, with direct oral anticoagulants (DOACs) gradually replacing warfarin.While this transition occurred earlier in some countries, limited data are available about its timeline in the Czech Republic.Objectives: This study aimed to analyse trends in OAC prescriptions in the Czech Republic from 2019 to 2024, focusing on the shift from warfarin to DOACs and the patterns of utilisation of individual DOACs.Methods: A retrospective analysis was conducted using national electronic prescription data from the State Institute for Drug Control (SKL).Annual drug consumption is presented as defined daily doses per thousand inhabitants per day (DDD/TID).Results: Total OAC utilisation increased from 18.83 to 26.70 DDD/TID between 2019 and 2024 (p < 0.01), with an average of 22.99 3.05 DDD/TID.DOACs surpassed warfarin in total prescriptions in 2021.Rivaroxaban (6.84 3.00 DDD/TID) and apixaban (5.24 2.43 DDD/TID) exhibited the highest growth, while dabigatran utilisation (3.00 0.66 DDD/TID) showed a halt in increase after 2022.Conclusion: DOACs have progressively replaced warfarin in the Czech Republic, but this transition occurred later than in other developed countries.This shift was likely influenced by local changes in prescribing restrictions.Further research is warranted to evaluate prescription patterns based on specific indications.
No takes yet. Share an insight, caveat, or question.
Veleta et al. (2025) conducted an observational in Conditions requiring oral anticoagulation (e.g., atrial fibrillation, venous thromboembolism). Direct oral anticoagulants (DOACs) in 2024 vs. Direct oral anticoagulants (DOACs) in 2019 was evaluated on DOAC utilisation (DDD/TID) (p=<0.01). Direct oral anticoagulant utilisation significantly increased from 7.78 to 22.54 DDD/TID between 2019 and 2024, surpassing warfarin as the predominant oral anticoagulant in the Czech Republic.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: